Clinical Trial Update: Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating safety and preliminary activity of eribulin mesylate in pediatric patients with relapsed/refractory rhabdomyosarcoma, n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Non-rhabdomyosarcoma Soft Tissue Sarcoma
• Rhabdomyosarcoma

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: Eisai Inc. | Conditions: Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2022-01-28